Conduit Pharmaceuticals logo
CDTConduit Pharmaceuticals
Trade CDT now
Conduit Pharmaceuticals primary media

About Conduit Pharmaceuticals

Conduit Pharmaceuticals (NASDAQ:CDT) is a clinical-stage biopharmaceutical company focusing on developing drugs for unmet medical needs. They prioritize assets overlooked by larger companies. Their pipeline includes a drug in Phase II for autoimmune diseases and a potential treatment for male infertility. The company is headquartered in San Diego, California.

What is CDT known for?

Snapshot

Public US
Ownership
2019
Year founded
4
Employees
San Diego, United States
Head office
1 of 294
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...

Operations

All Locations
United States

Produtos e/ou serviços de Conduit Pharmaceuticals

  • Drug Development: Conduit identifies promising drug candidates with the potential to address unmet medical needs.
  • Clinical Trials: They design and conduct clinical trials to test the safety and efficacy of their drug candidates.
  • Partnerships: Conduit may collaborate with other pharmaceutical companies to develop and commercialize their drugs.
  • Autoimmune Disease Treatments: Their current pipeline prioritizes drugs for autoimmune diseases like uveitis and Hashimoto's Thyroiditis.
  • Male Infertility Treatment: They're also exploring treatments for idiopathic male infertility.
  • Licensing: Conduit might license their developed drugs to other companies for further development or commercialization.

equipe executiva do Conduit Pharmaceuticals

  • Dr. Andrew ReganFounder, CEO & Director
  • Mr. James BlighCo-Founder, CFO & Director
  • Dr. Joanne M. HollandChief Scientific Officer

Connect with us

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relate to your unique circumstances.

Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of or reliance on the information provided directly or indirectly, by use of this platform.